Network Pharmacology-Guided Mechanism Study Uncovers Inhibitory Effect Of Mahuang Decoction On Lung Cancer Growth By Impeding Akt/Erk Signaling Pathways

Lung cancer (LC) ranks the leading cause of cancer-related death worldwide, due partially to the unsatisfactory therapeutic effect of the mainstream treatment. Alternatively, Chinese herb medicine (CHM) offers a bright perspective for treating complex diseases. Mahuang Decoction (MHD), a classic CHM formula, has been widely used in treating respiratory diseases in China for centuries, but its action mechanism has yet to be fully investigated. In this study, we first systemically explore the action mechanism of MHD by using network pharmacology and bioinformatic analysis tools, which uncovered a potential "new use of old drug" for MHD in cancer treatment. The therapeutic effect of MHD on LC was then validated by oral administration of MHD in the immunodeficient mice bearing xenografted LC tumors. To better understand the pharmacological activity of MHD against LC, we next constructed a drug/disease-target PPI network composed of 252 putative core therapeutic targets of MHD using Cytoscape. The subsequent enrichment analysis for these targets suggested that MHD could affect the apoptosis and cell cycle of LC cells via impeding Akt/ERK signaling pathways. Notably, these in silico analysis results were further validated by a series of cellular functional and molecular biological assays. Thus, our results show that MHD holds a great potential in LC treatment.